Application of methyl protocatechuate in preparation of medicine for improving intestinal barrier
By using protocatechate to improve the expression of intestinal barrier protein, the problem of intestinal barrier destruction in inflammatory bowel disease is solved, and the intestinal cell damage and the damage to the pathological structure of the mouse colon is significantly reduced, providing a Effective intestinal damage protection drugs.
Patent Information
- Application Number
- CN202411078652.7
- Authority / Receiving Office
- CN · China
- Patent Type
- Applications(China)
- Current Assignee / Owner
- Filing Date
- 2024-08-07
- Publication Date
- 2024-11-15
- Estimated Expiration
- Not applicable · inactive patent
AI Technical Summary
There is a lack of drugs to improve the intestinal barrier in the prior art, especially in inflammatory bowel disease. The destruction of the intestinal barrier leads to serious diseases. It is urgent to find natural products to repair the intestinal barrier.
Using protocatechate as the main active ingredient, its protective effect on intestinal cell damage and colon damage induced by dextran sodium sulfate was verified through in vitro and in vivo experiments, and improved intestinal barrier proteins ZO-1 and occludin Expression enhances intestinal barrier integrity.
Protocatechate significantly improved the disorder of Caco-2 cells and colon glands induced by sodium glucan sulfate, increased the number of goblet cells, maintained the integrity of the intestinal barrier, and reduced inflammatory infiltration and pathological injury, providing an effective protective drug for intestinal injury.
Smart Images

Figure CN118948826A_ABST
Abstract
Description
Technical Field
[0001] The invention belongs to the technical field of medicine and chemistry, and particularly relates to application of methyl protocatechuate in preparing a medicine for improving intestinal barrier. Background Art
[0002] According to the "Consensus on the Diagnosis and Treatment of Inflammatory Bowel Disease by the Inflammatory Bowel Disease Group of the Gastroenterology Branch of the Chinese Medical Association (2018, Beijing)", there are nearly 580,000 UC patients and nearly 170,000 Crohn's disease patients in China. It is estimated that by 2025, the number of patients with inflammatory bowel disease in my country will reach 1.5 million. Due to the low mortality rate of ulcerative colitis, the global burden is increasing. In the United States alone, the annual direct and indirect costs associated with ulcerative colitis are estimated to be between US$8.1 billion and US$14.9 billion. At present, Western medicine is not satisfactory in the treatment of intestinal diseases, and the search for drugs to treat intestinal diseases from natural products has a good market prospect. Among them, the English abbreviation for Crohn's disease is CD; the English abbreviation for inflammatory bowel disease is IBD; the English abbreviation for ulcerative colitis is UC; the English abbreviation for ulcerative colitis is UC.
[0003] The intestine is an organ that connects the body to the outside world. On the one hand, it plays a role in digestion and absorption, and on the other hand, it plays a role in resisting the invasion of external pathogens, bacteria and viruses. Therefore, a complete intestinal barrier plays an extremely important role in intestinal homeostasis. The intestinal barrier is mainly composed of four parts: mechanical barrier, chemical barrier, immune barrier and biological barrier. As the first barrier in the intestine, the mechanical barrier is composed of intestinal epithelial cells, enteroendocrine cells and tight junction complexes between cells. As a key part of the mechanical barrier, the tight junction complex is composed of claudin, occludin and zonula occludens-1 (ZO-1), which maintain the stability of the epithelial cell structure; the chemical barrier is composed of mucus glycoproteins and digestive juices secreted by intestinal epithelial cells, which can prevent bacteria from passing through the mucus layer and invading intestinal epithelial cells; the immune barrier is composed of intestinal lymphoid tissue and secretory immunoglobulin A, which can identify self or external antigens to trigger the body's immune response, thereby preventing the invasion of pathogens; the biological barrier is composed of intestinal flora, which can not only secrete repair factors, promote goblet cells to produce mucin, and strengthen tight junctions between cells, but also resist pathogenic bacteria from invading the intestine. In short, a complete intestinal barrier is the basis for resisting the occurrence of intestinal diseases.
[0004] Methyl protocatechuate is a phenolic ester extracted from plants such as Bauhinia bark, Brazilian berry, and French marigold. Studies have shown that methyl protocatechuate has good free radical scavenging, antioxidant, anti-inflammatory, and anti-fluoride lung toxicity effects. However, there are no reports on methyl protocatechuate improving intestinal barrier. Summary of the invention
[0005] In order to solve the problem in the prior art that there is no report on protocatechuic acid methyl ester improving the intestinal barrier, the present invention provides the use of protocatechuic acid methyl ester compounds in the preparation of drugs for improving the intestinal barrier.
[0006] The present invention tests whether methyl protocatechuate can improve the damage of dextran sulfate sodium (DSS) to epithelial cells (Caco-2 cells) in vitro, the regulation of intestinal barrier proteins ZO-1 and occludin, and the effect on transmembrane resistance. At the same time, the effect of methyl protocatechuate on dextran sulfate sodium (DSS)-induced mouse colon damage and the protective effect of mouse intestinal barrier were investigated in vivo. Studies have shown that methyl protocatechuate can significantly improve the damage of dextran sulfate sodium (DSS) to epithelial cells (Caco-2 cells), improve the disorder of mouse colon glands induced by dextran sulfate sodium (DSS), the loss of goblet cells, the reduction of tight junction proteins, and improve the intestinal barrier. The specific scheme is as follows:
[0007] The invention provides application of methyl protocatechuate in preparing a medicine for improving intestinal barrier.
[0008] Preferably, the protocatechuic acid methyl ester is used to improve the damage of sodium dextran sulfate to intestinal epithelial cells, thereby improving the intestinal barrier. In the embodiment of the present invention, taking the intestinal epithelial cells: Caco-2 as an example, a Caco-2 cell damage model induced by sodium dextran sulfate was constructed. Experimental verification shows that protocatechuic acid methyl ester significantly protects the integrity of the in vitro intestinal barrier model constructed by Caco-2 cells, resists the barrier damage induced by sodium dextran sulfate, and maintains the normal expression of key tight junction proteins ZO-1 and occludin in the intestinal barrier. The English name of sodium dextran sulfate is DSS.
[0009] The present invention also provides the use of the protocatechuic acid methyl ester in the preparation of a drug for improving the disorder of the mouse colon glands, the loss of goblet cells, and the reduction of tight junction proteins induced by sodium dextran sulfate. Through histopathological sections, it was found that protocatechuic acid methyl ester had a significant protective effect on the mouse colon barrier damage induced by sodium dextran sulfate, which was manifested by a relatively normal colon structure, a relatively complete gland, and a large number of goblet cells. The detection of colon tight proteins by immunoblotting confirmed the protective effect of protocatechuic acid methyl ester on the colon barrier.
[0010] Preferably, the drug contains the protocatechuic acid methyl ester as the main active ingredient and further contains a pharmaceutically acceptable carrier or excipient to be prepared into a pharmaceutically acceptable dosage form.
[0011] Preferably, it is used for protecting the colonic injury and intestinal barrier of mice induced by sodium dextran sulfate, reducing the inflammatory infiltration and pathological damage of the colon of mice, protecting the integrity of the colonic barrier, and maintaining the normal morphology and quantity of key tissues such as colon glands and goblet cells.
[0012] Preferably, the effective concentration of the protocatechuic acid methyl ester in the drug is 10 mg / kg to 20 mg / kg.
[0013] Preferably, the drug dosage forms include oral dosage forms, injection dosage forms, and inhalation dosage forms. The oral dosage forms here refer to oral regular release dosage forms, including ordinary tablets (tablets, enteric-coated tablets, coated tablets, film-coated tablets, sugar-coated tablets, extract tablets, dispersible tablets, scratched tablets), hard capsules, soft capsules (pills), and enteric-coated capsules. Injection dosage forms include injection solutions, injection solutions for intravenous drip, injection suspensions, sterile powders for injection, intravenous injections, water injections, injection emulsions, powder injections, injections, sterile powder injections, and freeze-dried powder injections. The route of administration of inhalation dosage forms is: absorption by lung epithelial cells or respiratory mucosa → entering the blood circulation. Characteristics of inhalation administration: fast onset of action, comparable to intravenous injection. Large surface area of the lungs. First-pass elimination can be avoided, which is particularly suitable for lung diseases.
[0014] Preferably, the medicine includes tablets, pills, powders, injections, capsules, and oral liquids.
[0015] Preferably, the drug-assisted carrier includes one or more of a surfactant, a disintegrant, a solubilizer, a lubricant, and a binder.
[0016] Surfactants are substances that have strong surface activity and can significantly reduce the surface tension of liquids. Common surfactants include higher fatty acid salts, sulfates, benzalkonium chloride, etc.
[0017] Disintegrants refer to substances that can quickly break tablets into fine particles in gastrointestinal fluid, so that the functional ingredients can be quickly dissolved and absorbed to exert their effects. Most of these substances have good water absorption and swelling properties, thus achieving tablet disintegration. Commonly used disintegrants include: dry starch, sodium carboxymethyl starch, low-substituted hydroxypropyl cellulose, cross-linked sodium carboxymethyl cellulose, cross-linked polyvinylpyrrolidone, and effervescent disintegrants.
[0018] Dissolution promoters are auxiliary agents that "promote" drug dissolution, including sodium benzoate, sodium salicylate, p-aminobenzoic acid, etc.
[0019] Lubricants include magnesium stearate, micronized silica gel, talc, hydrogenated vegetable oil, polyethylene glycols, and sodium lauryl sulfate.
[0020] Adhesives are sticky substances that use their stickiness to connect two separate materials together. There are many types of pharmaceutical excipient adhesives, the most common of which is starch.
[0021] The present invention also provides a drug for improving intestinal barrier, wherein the drug is a solution prepared by using the protocatechuic acid methyl ester as a raw material;
[0022] The concentration of the protocatechuic acid methyl ester in the solution is 10 μM-20 μM.
[0023] Compared with the prior art, the present invention has the following beneficial effects:
[0024] The invention provides application of methyl protocatechuate in preparing a medicine for improving intestinal barrier, and provides a medicine for treating intestinal diseases.
[0025] The incidence of inflammatory bowel disease increases year by year. Inflammatory bowel disease is accompanied by severe intestinal barrier damage, and it is urgent to find natural drugs to improve the intestinal barrier. The present invention investigates whether methyl protocatechuate can reduce the damage of intestinal epithelial cells in vivo and in vitro. The Caco-2 cell injury model induced by dextran sulfate sodium (DSS) and the Bab / c mouse intestinal injury model were treated with or without methyl protocatechuate, and the drug was observed to regulate the tight junction protein in the Caco-2 cell injury model, the effect on transmembrane resistance, and the pathological damage to the colon structure of mice. The results showed that compared with the Caco-2 cell injury model group without methyl protocatechuate treatment, the expression of tight junction protein in Caco-2 cells treated with methyl protocatechuate was significantly increased, which could significantly inhibit the decrease in transmembrane resistance and protect the monolayer barrier from damage. Compared with the model mice without methyl protocatechuate treatment, the colon pathological structure was significantly improved, the colon goblet cell loss was significantly improved, and the reduction of colon tight junction protein was significantly improved. Therefore, methyl protocatechuate is a promising natural product that can improve the pathological condition of intestinal damage in intestinal diseases. BRIEF DESCRIPTION OF THE DRAWINGS
[0026] Figure 1 The figure is a molecular structure diagram of protocatechuic acid methyl ester in the present invention.
[0027] Figure 2 The present invention is the regulatory effect of protocatechuic acid methyl ester on tight junction proteins in the DSS-induced Caco-2 cell injury model; wherein, Figure 2 A in the figure represents the regulation of methyl protocatechuate on tight junction proteins ZO-1 and occludin in the DSS-induced Caco-2 cell injury model; Figure 2 B in the figure is a statistical graph of protein grayscale values. Con is the normal group, DSS is the model group, MP is the protocatechuic acid methyl ester administration group, Low represents a low dose of 10 μM protocatechuic acid methyl ester, and High represents a high dose of 20 μM protocatechuic acid methyl ester.
[0028] Figure 3The effect of protocatechuic acid methyl ester on the transmembrane resistance of the Caco-2 cell injury model induced by DSS in the present invention is shown in FIG. Figure 3 A in the figure is the transmembrane resistance value in Transwell after Caco-2 monolayer barrier culture for 21 days; Figure 3 B in the figure is a statistical graph; Con is the normal group, DSS is the model group, and MP is the protocatechuic acid methyl ester-administered group.
[0029] Figure 4 It is the HE staining picture of the colon pathological structure in the present invention; wherein, Con is the normal group, Mod is the DSS model group, SASP is the group administered with sulfasalazine after DSS modeling, and MP is the group administered with methyl protocatechuate.
[0030] Figure 5 The present invention is the regulatory effect of protocatechuic acid methyl ester on tight junction proteins in the DSS-induced intestinal injury model of mice, wherein: Figure 5 A in the figure represents the regulation of methyl protocatechuate on tight junction proteins ZO-1 and occludin in the DSS-induced intestinal injury model in mice; Figure 5 B in the figure is a statistical graph of protein grayscale values; Con is the normal group, DSS is the model group, MP is the protocatechuic acid methyl ester administration group, Low represents a low dose of 10 mg / kg protocatechuic acid methyl ester, and High represents a high dose of 20 mg / kg protocatechuic acid methyl ester. DETAILED DESCRIPTION
[0031] The present invention is described in detail below in conjunction with the accompanying drawings and specific examples, but should not be construed as limiting the present invention. Unless otherwise specified, the technical means used in the following examples are conventional means well known to those skilled in the art, and the materials, reagents, etc. used in the following examples, unless otherwise specified, can be obtained from commercial sources.
[0032] Reagents and materials, cells, experimental animals and instruments are as follows:
[0033] 1. Reagents;
[0034] Protocatechuic acid methyl ester was purchased from Chengdu Aifa Biotechnology Co., Ltd. The structure of protocatechuic acid methyl ester is as follows Figure 1 shown.
[0035] Dextran sulfate sodium was purchased from Abe Medical Device Trading (Shanghai) Co., Ltd.; ZO-1 antibody was purchased from Abcam; occludin antibody was purchased from Abcam.
[0036] Sulfasalazine (SASP) was purchased from Shanghai Aladdin Biochemical Technology Co., Ltd.
[0037] 2. Cells:
[0038] Caco-2 cells were purchased from Wuhan Pronocell Life Science Technology Co., Ltd.
[0039] 3. Experimental animals
[0040] Bab / c mice were purchased from the Experimental Animal Center of Three Gorges University.
[0041] 4. Instruments:
[0042] EVOM2 transmembrane cell resistance meter: World Precision Instrument Trading (Shanghai) Co., Ltd.
[0043] Example 1
[0044] 1. Methods
[0045] 1. In vitro experiments
[0046] 1.1 Regulatory effect of methyl protocatechuate on tight junction proteins in the DSS-induced Caco-2 cell injury model
[0047] Dextran sulfate sodium (DSS) was used to create a Caco-2 cell injury model, and 10μM and 20μM protocatechuic acid methyl ester were given for intervention. Proteins were extracted, and Western blot was used to detect the expression of intestinal barrier proteins ZO-1 and occludin.
[0048] Caco-2 cells were inoculated in six-well plates. When the cells were fully differentiated and the growth rate reached 70%, all the culture medium was discarded and the cells were divided into groups. The normal group was given DMEM high-glucose medium containing 10% fetal bovine serum by mass, the model group was given 2.5% DSS by volume on the basis of the normal group, and the drug-treated group was given 10μM and 20μM protocatechuic acid methyl ester on the basis of the model group. Cultured in the above culture system for 24h. After the culture, the supernatant was discarded, the total protein of each group of cells was extracted with RIPA reagent, and SDS-PAGE electrophoresis was performed. Western blot was used to detect the expression of intestinal barrier protein ZO-1, Occludin and internal reference protein β-actin.
[0049] 1.2 Protective effect of methyl protocatechuate on barrier tightness of Caco-2 cell injury model induced by DSS
[0050] The Caco-2 cell injury model was created by using dextran sulfate sodium (DSS), and 10μM and 20μM protocatechuic acid methyl ester were given for intervention. The Transwell transmembrane resistance TEER was measured using the EVOM2 transmembrane cell resistance meter to detect the density and integrity of the Caco-2 monolayer barrier. The specific steps are as follows:
[0051] First, a Caco-2 monolayer barrier was established. 0.5 mL of DMEM high-glucose medium containing 10% fetal bovine serum was added to each well of a 24-well plate. The Corning Transwell to be inoculated was placed in the 24-well plate and pre-balanced in an incubator for 2 h to improve cell adhesion. The Caco-2 cell concentration was adjusted to 2 × 10 5 / ml, inoculated inside the Transwell, the culture medium was changed every 2 days, and the cells were cultured in the incubator for 21 days. The cell status was checked daily using an optical microscope to observe the cell growth density and whether there was sheet shedding. The Transwell transmembrane resistance TEER was measured using an EVOM2 transmembrane cell resistance meter on days 3, 6, 9, 12, 15, 18, and 21 to detect the density and integrity of the Caco-2 monolayer model. At the same time, a blank chamber was set up, and the blank chamber was treated according to the same steps as above to measure the blank resistance value.
[0052] The calculation formula is as follows: TEER (Ω·cm 2 ) = (actual resistance value - blank resistance value) × Transwell chamber membrane area.
[0053] After 21 days of Caco-2 culture, the transmembrane resistance in Transwell was stable at 600Ω·cm 2 The above single-layer barrier was used to detect the protective effect of protocatechuic acid methyl ester on barrier damage. The experiment was divided into normal group, DSS model group, protocatechuic acid methyl ester 10μM group, and protocatechuic acid methyl ester 40μM group. The modeling and drug delivery system were the same as 1.1.
[0054] The Caco-2 monolayer membrane was rinsed twice with PBS buffered saline solution, 300 μL of each system was added to the Transwell, and 700 μL of each system was added to the 24-well plate, with 3 wells set up in each group. After culturing at 37°C in an incubator for 24 hours, the Transwell transmembrane resistance TEER was detected using an EVOM2 transmembrane cell resistance meter.
[0055] 2. In vivo experiments
[0056] Dextran sulfate sodium (DSS) was used to induce the ulcerative colitis model in Bab / c mice. Protocatechuic acid methyl ester was administered at a concentration of 10 mg / kg and 20 mg / kg. The colon was stained with HE to observe the pathological damage of colon structure, and the expression of intestinal barrier proteins ZO-1 and occludin was detected by Western blot. The improvement of protocatechuic acid methyl ester on DSS-induced colon damage in mice was evaluated.
[0057] Forty SPF male Bab / c mice, weighing 20g±0.5g, were randomly divided into four groups after adaptive feeding for 3 days, with 10 mice in each group. The normal group drank distilled water freely, and the mice in the model group and the drug-treated group drank 3% DSS solution freely. At the same time, the mice in the drug-treated group were gavaged with 10mg / kg or 20mg / kg of protocatechuic acid methyl ester solution every day. After 7 days of the above intervention, the mice were killed, and part of the colon tissue was fixed in 4% paraformaldehyde solution, embedded in paraffin, sliced into 5μM slices by microtome, stained with hematoxylin and eosin, and photographed under a microscope. The remaining 30mg of colon tissue was taken, and the total protein of each group of animals was extracted with RIPA reagent, and SDS-PAGE electrophoresis was performed, and Western blot was used to detect the expression of intestinal barrier protein ZO-1, Occludin and internal reference protein β-actin.
[0058] 2. Results
[0059] 1. Methyl protocatechuate can inhibit the decrease of tight junction proteins in the DSS-induced Caco-2 cell injury model
[0060] Compared with the normal group, the tight junction proteins ZO-1 and occludin in Caco-2 cells after DSS modeling were significantly reduced. After drug intervention, the reduction of tight junction proteins ZO-1 and occludin was significantly improved, with statistical significance. Figure 2 As shown. Among them, Figure 2 A in the figure represents the regulation of methyl protocatechuate on tight junction proteins ZO-1 and occludin in the DSS-induced Caco-2 cell injury model; Figure 2 B in the figure is a statistical graph of protein grayscale values. Con is the normal group, DSS is the model group, MP is the protocatechuic acid methyl ester administration group, Low represents a low dose of 10 μM protocatechuic acid methyl ester, and High represents a high dose of 20 μM protocatechuic acid methyl ester.
[0061] From the above, it can be seen that methyl protocatechuate can significantly improve the reduction of tight junction proteins in the DSS-induced Caco-2 cell injury model.
[0062] 2. Methyl protocatechuate has a protective effect on the monolayer barrier of the DSS-induced Caco-2 cell injury model
[0063] After 21 days of Caco-2 monolayer barrier culture, the transmembrane resistance in the Transwell was higher than 600Ω·cm2. After 24 hours of 2.5% DDS treatment, the transmembrane resistance of the model group decreased, which was significantly different from that of the control group (P<0.05). Both low-dose 10μM and high-dose 20μM protocatechuic acid methyl ester administration could significantly inhibit the decrease in transmembrane resistance (P<0.05), protecting the monolayer barrier from damage, and it was dose-dependent. Figure 3 As shown. Among them, Figure 3 A in the figure is the transmembrane resistance value in Transwell after Caco-2 monolayer barrier culture for 21 days; Figure 3 B in the figure is a statistical graph; Con is the normal group, DSS is the model group, and MP is the protocatechuic acid methyl ester-administered group.
[0064] From the above, it can be seen that methyl protocatechuate can significantly inhibit and improve the decrease in transmembrane resistance value in the DSS-induced Caco-2 cell injury model, thereby protecting the monolayer barrier from damage.
[0065] 3. Methyl protocatechuate can improve the destruction of colon pathological structure and loss of goblet cells in DSS-induced mice
[0066] Compared with the normal group, the colon of mice induced by DSS was severely damaged, the intestinal barrier was severely damaged, and the goblet cells were significantly lost. After intervention with protocatechuic acid methyl ester, the intestinal barrier damage was significantly alleviated. Figure 4 shown.
[0067] From the above, it can be seen that protocatechuic acid methyl ester can significantly improve the colon pathological structure and goblet cell loss of DSS-induced mice.
[0068] 4. Methyl protocatechuate can inhibit the decrease of tight junction proteins in the DSS-induced intestinal injury model of mice
[0069] Compared with the normal group, the tight junction proteins ZO-1 and occludin in mice after DSS modeling were significantly reduced. After drug intervention, the reduction of tight junction proteins ZO-1 and occludin was significantly improved, with statistically significant differences. Figure 5 As shown. Among them, Figure 5 A in the figure represents the regulation of methyl protocatechuate on tight junction proteins ZO-1 and occludin in the DSS-induced intestinal injury model in mice; Figure 5 B in the figure is a statistical graph of protein grayscale values; Con is the normal group, DSS is the model group, MP is the protocatechuic acid methyl ester administration group, Low represents a low dose of 10 mg / kg protocatechuic acid methyl ester, and High represents a high dose of 20 mg / kg protocatechuic acid methyl ester.
[0070] From the above, it can be seen that protocatechuic acid methyl ester can significantly improve the loss of colon tight junction proteins in mice induced by DSS.
[0071] In summary, the present invention creatively discovered that the protocatechuic acid methyl ester of the present invention can inhibit the decrease of tight junction proteins of intestinal epithelial cells induced by DSS, protect the intestinal barrier, and can be used as a drug for protecting intestinal damage.
[0072] It should be noted that when the claims of the present invention involve numerical ranges, it should be understood that the two endpoints of each numerical range and any numerical value between the two endpoints can be selected. In order to avoid redundancy, the present invention describes a preferred embodiment.
[0073] Although the preferred embodiments of the present invention have been described, those skilled in the art may make other changes and modifications to these embodiments once they have learned the basic creative concept. Therefore, the appended claims are intended to be interpreted as including the preferred embodiments and all changes and modifications that fall within the scope of the present invention.
[0074] Obviously, those skilled in the art can make various changes and modifications to the present invention without departing from the spirit and scope of the present invention. Thus, if these modifications and variations of the present invention fall within the scope of the claims of the present invention and their equivalents, the present invention is also intended to include these modifications and variations.
Claims
1. Application of methyl protocatechuate in the preparation of drugs for improving intestinal barrier.
2. The use according to claim 1, characterized in that: The protocatechuic acid methyl ester is used to improve the damage of sodium dextran sulfate to intestinal epithelial cells, thereby improving the intestinal barrier.
3. Use of the protocatechuic acid methyl ester according to claim 1 in the preparation of a drug for improving the disorder of the colon glands, the loss of goblet cells and the reduction of tight junction proteins in mice induced by dextran sulfate sodium.
4. The use according to claim 3, characterized in that: The medicine uses the protocatechuic acid methyl ester as the main active ingredient and also contains pharmaceutically acceptable carriers or auxiliary materials to be prepared into a pharmaceutically acceptable dosage form.
5. The use according to claim 4, characterized in that: Used for the protection of mouse colon damage induced by dextran sulfate sodium and the intestinal barrier of mice.
6. The use according to claim 4, characterized in that: The effective concentration of the protocatechuic acid methyl ester in the medicine is 10 mg / kg to 20 mg / kg.
7. The use according to claim 4, characterized in that: The pharmaceutical dosage forms include oral dosage forms, injection dosage forms, and inhalation dosage forms.
8. The use according to claim 7, characterized in that The medicine includes tablets, pills, powders, injections, capsules, and oral liquids.
9. The use according to claim 4, characterized in that: The drug-assisted carrier includes one or more of a surfactant, a disintegrant, a solubilizer, a lubricant, and a binder.
10. A drug for improving intestinal barrier, characterized in that: The drug is a solution prepared using the protocatechuic acid methyl ester described in claim 1 as a raw material; The concentration of the protocatechuic acid methyl ester in the solution is 10 μM-20 μM.
Citation Information
Patent Citations
Herbal Nutraceutical Formulation to Reduce Oxidative Stress, Viral and Microbial Infections, and Inflammation
US20190209634A1
